Vaccine‐induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV‐19 is rare in Asia
Open Access
- 15 January 2022
- journal article
- editorial
- Published by Elsevier BV in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (1), e12644
- https://doi.org/10.1002/rth2.12644
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Platelet count as an important prognostic factor for vaccine-induced immune thrombotic thrombocytopeniaBlood Research, 2021
- COVID‐19 Vaccine‐Associated Cerebral Venous Thrombosis in GermanyAnnals of Neurology, 2021
- Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopeniaThrombosis Research, 2021
- Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case SeriesFrontiers in Neurology, 2021
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 VaccinationThe New England Journal of Medicine, 2021
- Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopeniaThrombosis Research, 2021
- Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort studyBMJ, 2021
- Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patientsThrombosis Research, 2014